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Abstract
Background: The peptide neurotransmitter N-Acetylaspartylglutamate (NAAG) is the third most
prevalent transmitter in the mammalian central nervous system. Local, intrathecal and systemic
administration of inhibitors of enzymes that inactivate NAAG decrease responses to inflammatory
pain in rat models. Consistent with NAAG's activation of group II metabotropic glutamate
receptors, this analgesia is blocked by a group II antagonist.
Results: This research aimed at determining if analgesia obtained following systemic administration
of NAAG peptidase inhibitors is due to NAAG activation of group II mGluRs in brain circuits that
mediate perception of inflammatory pain. NAAG and NAAG peptidase inhibitors, ZJ43 and 2-
PMPA, were microinjected into a lateral ventricle prior to injection of formalin in the rat footpad.
Each treatment reduced the early and late phases of the formalin-induced inflammatory pain
response in a dose-dependent manner. The group II mGluR antagonist reversed these analgesic
effects consistent with the conclusion that analgesia was mediated by increasing NAAG levels and
the peptide's activation of group II receptors.
Conclusion: These data contribute to proof of the concept that NAAG peptidase inhibition is a
novel therapeutic approach to inflammatory pain and that these inhibitors achieve analgesia by
elevating synaptic levels of NAAG within pain processing circuits in brain.
Introduction
The peptide N-acetylaspartylglutamate (NAAG) is by far
the most prevalent [1] and widely distributed co-transmit-
ter in the mammalian nervous system[2,3]. It is co-
expressed in discrete subsets of neurons with most small
amine transmitters, including glutamate and GABA. Con-
sistent with other neuropeptides, NAAG is released under
conditions of high neuronal activity and acts at presynap-
tic receptors [4-6]. Synaptically released NAAG activates
the group II metabotropic glutamate receptors [mGluR3
>> mGluR2; [6-8]]. These receptors are expressed on astro-
cytes where they stimulate release of trophic factors and
on presynaptic axons where they inhibit transmitter
release [5,6,9,10]. Two enzymes that inactivate synapti-
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cally released NAAG, glutamate carboxypeptidase II and
III, have been cloned and characterized [11-15]. Potent
inhibitors (IC50 = 1–5 nM) of these enzymes are being
tested in animal models of neurological conditions that
are mediated by high levels of glutamate release [16-18].
While these NAAG peptidase inhibitors do not possess
direct agonist activity at ionotropic or metabotropic gluta-
mate receptors, they, like group II mGluR agonists, are
effective in reducing perception of inflammatory, neuro-
pathic pain and bone cancer pain in rat models [19-24].
Consistent with the conclusion that inhibitors of NAAG
peptidases achieve analgesia by elevating the degree of
NAAG activation of a group II mGluR, group II antago-
nists completely reverse these analgesic actions.
While group II mGluR agonists influence nociceptive
responses of primary sensory afferents [19,20,25-28], the
widespread distribution of NAAG, NAAG peptidase activ-
ity [29] and group II mGluRs within pain pathways
(reviewed in [30,31]) suggests that these receptors in the
brain also might modulate pain perception following acti-
vation by NAAG. Group II mGluRs are upregulated in the
central nervous system in response to inflammatory pain
states [32-35]. In the periaquaductal grey, a brain region
that contributes to descending modulation of nociceptive
transmission within the spinal cord [36], group II mGluR
agonists act presynaptically to reduce GABAergic trans-
mission [37]. Speculation that this action contributes to
analgesia derives from observations that opioid analgesia
induced at the level of the periaquaductal grey also is
mediated by reduction in GABAergic input to descending
projections [38,39]. In this first test of the role of NAAG in
regulation of pain perception via brain pain pathways, we
administered NAAG and two NAAG peptidase inhibitors
into the rat lateral ventricle prior to induction of inflam-
matory pain.
Methods
These experiments were executed in adherence with the
guidelines of the Committee for Research and Ethical
Issues of the International Association for the Study of
Pain (1983). They were performed according to a protocol
approved by the Institutional Animal Care Committee of
Chiba University, Chiba, Japan. Male Sprague-Dawley rats
(250 – 300 g, Japan SLC, Shizuoka, Japan) were prepared
with ICV catheters and examined for the effect of the
agents on the formalin test of inflammatory pain.
ICV cannulae
Implantation of the intracerebroventricular (ICV) injec-
tion cannula into the right lateral ventricle was performed
stereotaxically under halothane anesthesia. Stainless steel
guide cannulae (24 gauge, 0.64 mm outer diameter, 15
mm long) were stereotaxically placed through a burr hole
(0.5 mm caudal to coronal suture and 1 mm lateral to sag-
ital suture; 3 mm deep to the dura) and affixed to the skull
with stainless steel screws and cranioplastic cement. In
our experience, drug injection via the canulae is optimal
about 4 days after implantation as the canulae have not
plugged with cells by that time, in contrast to 7 days after
implantation. Thus, ICV cannula implantation was per-
formed 4 days before the formalin test. All animals dis-
played normal feeding and drinking behaviors
postoperatively. Rats showing neurological deficits were
not studied.
Formalin test
To carry out the formalin test, 50 μl of 5% formalin was
injected subcutaneously (SC) into the dorsal surface of the
right hind paw with a 25-gauge needle under brief haloth-
ane anesthesia. Within 1 min after the formalin injection,
spontaneous flinching of the injected paw could be
observed. Flinching is readily discriminated and is charac-
terized as a rapid and brief withdrawal or flexion of the
injected paw. This pain-related behavior was quantified
by counting the number of flinches for 1 min periods at 1
– 2 and at 5 – 6 min, and then for 1 min periods at inter-
vals during the period from 10 to 60 min after the injec-
tion. Two phases of spontaneous flinching behavior, an
initial acute phase (phase 1: during the first 6 min after the
formalin injection) and a prolonged tonic phase (phase 2:
beginning about 10 min after the formalin injection),
were observed. After the observation period, the animals
were immediately killed with an overdose of barbiturate.
Four to six rats were used for each treatment group
reported here.
Behavioral analysis
The general behavior of each rat was carefully observed
and tested. Motor functions were evaluated by the per-
formance of two specific behavioral tasks, as follows. 1)
The placing/stepping reflex: this response was evoked by
drawing the dorsum of either hindpaw over the edge of a
table top. In normal animals, this stimulus elicits an
upward lifting of the paw onto the surface of the table,
called stepping. Animals with any degree of hind limb
flaccidity will demonstrate an altered or absent reflex. 2)
The righting reflex: an animal placed horizontally with its
back on the table will normally show an immediate coor-
dinated twisting of the body around its longitudinal axis
to regain its normal position on its feet. Animals display-
ing ataxic behavior will show a decreased ability to right
themselves. To quantify the evaluation of motor func-
tions, both tasks were scored on a scale of 0 to 2 in which
0 = absence of function and 2 = normal motor functions.
Animals that were able to perform the motor tasks but did
so more slowly than normal animals were assigned a score
of 1. For example, the reflex withdrawal is typically imme-
diate. Rats demonstrating a non-immediate reflex were
scored 1. The normal righting reflex also is prompt andMolecular Pain 2008, 4:31 http://www.molecularpain.com/content/4/1/31
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successful. Rats that either delayed the attempt or who
were ultimately but not immediately successful were
scored 1.
Drugs
(S)-2-[3-[(S)-1-carboxy-3-methylbutyl]ureido]pentanedi-
oic acid (ZJ43) was synthesized following methods previ-
ously described [40]. ZJ43 (molecular weight = 304.3) is
an unsymmetrical urea, which was prepared by the addi-
tion reaction of an isocyanate, generated in situ from the
tosylate salt of glutamic acid dibenzyl ester and triphos-
gene in the presence of Et3N, with the second amino acid
benzyl ester component. The subsequent debenzylation
of the key intermediate by the catalytic hydrogenation
affords ZJ43 in the final form. 2-(phosphonomethyl) pen-
tanedioic acid (2-PMPA, molecular weight = 314) was
purchased from Alexis Biochemicals, (San Diego, CA,
USA). ZJ45 and 2-PMPA are NAAG peptidase inhibitors
[16-18]. NAAG was purchased from Tocris (Bristol, UK).
LY341495, a highly selective group II metabotropic gluta-
mate receptor antagonist [41], was purchased from Tocris.
The ICV administered drugs were delivered in a total vol-
ume of 3 μl.
Experimental protocol
ZJ43, 2-PMPA or NAAG were administered ICV 10 min
before the formalin injection. To obtain control data,
vehicle (saline) was injected ICV (n = 5). To verify that the
analgesic effect of ICV administered drugs on the formalin
test was mediated by the activation a group II mGluR, 1
mg/kg of LY341495 was administered intraperitoneally
(i.p.) 10 min before the ICV injection of drugs. The effect
of intraperitoneal (i.p.) administration of 1 mg/kg of
LY341495 on the formalin test also was examined.
Statistical analyses
For the dose-response analysis, data from phase 1 (0 – 6
min) and phase 2 (10 – 60 min) observations were con-
sidered separately. The cumulative instances of formalin-
evoked flinches during the phase 1 and phase 2 were cal-
culated for each rat. To evaluate the dose-dependence,
one-way analysis of variance (ANOVA) was used. Pub-
lished data strongly suggest that underlying mechanisms
that generate the phase 1 response is different from those
that generate the phase 2 response. Thus, for the dose-
response analysis, we considered phase 1 and phase 2
responses as independent samples. For multiple compari-
sons, Tukey's test was used. For comparison of the pain
response in the peptidase inhibitor group versus the
group that was treated with inhibitor and the group II
antagonist, the unpaired t-test (two tailed) was used.
Whenever appropriate, results are expressed as mean ±
SEM. Critical values that reached a p < 0.05 level of signif-
icance were considered significant.
Results
Behavioral analysis
ICV injection of 100 μg of ZJ43, caused restlessness in all
animals and 20% of the rats receiving 100 μg of ZJ43
scored 1 (impairment of motor function) in the placing/
stepping reflex and righting reflex. After ICV injection of
10 μg or less of NAAG, ZJ43 or 2-PMPA, all animals scored
2 (normal motor function) in the placing/stepping reflex
and righting reflex tests. As a result, 10 μg was the highest
dose of ZJ43 and 2-PMPA injected into the lateral ventri-
cle in this study. After the i.p. administration of 1 mg/kg
of LY341495, all animals scored 2 (normal motor func-
tion) in the placing/stepping reflex and righting reflex
tests.
Responses in formalin model of inflammatory pain
ICV injection of ZJ43 (Figure 1a), 2-PMPA (Figure 1b) or
NAAG (Figure 1c) decreased the sum of flinches induced
by formalin injection into the footpad while the group II
mGluR agonist LY341495 alone (Figure 1c) had no
detectable effect. Pretreatment with the group II mGluR
antagonist LY341495 (1 mg/kg, i.p.) blocked the analge-
sic effect of 10 μg of ZJ43 or 2-PMPA on both phases of the
flinching behavior (Figures 1a and 1b; phase 1: p < 0.01;
phase 2: p < 0.01, by t-test). LY341495 similarly antago-
nized the analgesic effect of 10 μg of NAAG on the phase
2, but not phase 1, flinching behavior (Figure 1c; phase 1:
p > 0.2; phase 2: p < 0.005, by t-test).
The NAAG peptidase inhibitors reduced phase 1 and
phase 2 flinching behaviors in a dose-dependent manner
relative to saline treated rats (Figures 2a and 2b; phase 1:
p < 0.01; phase 2: p < 0.01 by ANOVA). Similarly, ICV
injection of NAAG itself decreased the sum of flinches, in
both phases of the flinching behavior in a dose-depend-
ent manner between 1 and 10 μg (Figures 2a and 2b;
phase 1: p < 0.05; phase 2: p < 0.01 by ANOVA). The max-
imal effect of the peptide appeared to be less than that
obtained by the peptidase inhibitors. Ten μg of NAAG
provided a maximal effect inasmuch as 100 μg of NAAG
gave no greater reduction (Figure 2a and 2b).
Discussion
We previously reported that systemic, intrathecal and
local application of NAAG peptidase inhibitors reduced
pain perception in rat models of inflammatory, neuro-
pathic and bone cancer induced pain and that these effects
are blocked by co-application of a group II mGluR [20-
24]. These and other data support the conclusion that the
analgesic effects of NAAG peptidase inhibition are medi-
ated by increased activation of presynaptic group II
mGluRs and a subsequent reduction in transmitter release
in those neuronal circuits in which NAAG and the pepti-
dase activity are expressed [reviewed in [16]]. However, it
was not clear from these data if systemic application ofMolecular Pain 2008, 4:31 http://www.molecularpain.com/content/4/1/31
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NAAG peptidase inhibitors achieved analgesia by activa-
tion of group II mGluRs in brain pain pathways. This
research ultimately is aimed at testing the concept that
NAAG peptidase inhibition represents a clinically signifi-
cant and completely new strategy for the treatment of
inflammatory and neuropathic pain. As such, defining the
locus of action of these peptidase inhibitors relative to
pain perception is an issue of central importance. The data
presented here support the conclusion that while the spi-
nal cord and sensory neurons represent loci at which
NAAG peptidase inhibition may contribute to analgesia,
there also is at least one locus in the brain where NAAG
directly mediates analgesia and that this brain region is
accessible via the lateral ventricles. Given the quantities of
the ZJ43 and 2-PMPA that are required locally [20] and
intrathecally [21] to obtain analgesia, it is possible that
the primary target for systemically applied NAAG pepti-
dase inhibitor-mediated analgesia is in the brain and/or
brain stem.
Since the inhibitors were infused into the right ventricle
and the inflammation was induced in the ipsilateral foot-
Effects of intracerebroventricular (ICV) injection of 10 μg of ZJ43 (a), 2-PMPA (b) or NAAG (c) on the time course of the  flinches observed after the formalin injection into the dorsal surface of the right rat hind-paw Figure 1
Effects of intracerebroventricular (ICV) injection of 10 μg of ZJ43 (a), 2-PMPA (b) or NAAG (c) on the time 
course of the flinches observed after the formalin injection into the dorsal surface of the right rat hind-paw. 
Drugs were administered 10 min before the formalin injection. The group II mGluR antagonist LY341495 (1mg/kg, i.p.) was 
injected 10 min before ZJ43, 2-PMPA, NAAG or saline (d). The number of flinches/min is plotted vs time after the formalin 
injection. NAAG and the NAAG peptidase inhibitors ZJ43 and 2-PMPA significantly reduced both phases of the response to 
formalin injection (see text for statistical assessment). The effects of the peptidase inhibitors were blocked by the LY341495 as 
was the effect of NAAG on phase 2 of the response to formalin. Each line represents the group mean and S.E.M. of four to six 
rats.Molecular Pain 2008, 4:31 http://www.molecularpain.com/content/4/1/31
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Dose-response curves for ICV injection of ZJ43, 2-PMPA and NAAG representing the cumulative instances of formalin evoked  flinches during the phase 1 (a) and the phase 2 (b) Figure 2
Dose-response curves for ICV injection of ZJ43, 2-PMPA and NAAG representing the cumulative instances of 
formalin evoked flinches during the phase 1 (a) and the phase 2 (b). ZJ43, 2-PMPA and NAAG reduced the number of 
phase 1 and the phase 2 flinching behaviors in a dose dependent manner. Each point represents the group mean and S.E.M. of 
responses by groups of 5–6 rats. * <0.05 and ** <0.005 versus rats given saline ICV prior to formalin-induced inflammation.Molecular Pain 2008, 4:31 http://www.molecularpain.com/content/4/1/31
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pad, it seems likely that the inhibitors were not acting
proximal to this ventricle but rather that the compounds
were affecting the broader periventricular tissue of the
brain including the contralateral descending pain modu-
lating pathway in the periaquaductal grey. The periaquad-
uctal grey is an important locus in the pathway for opioid
mediated analgesia. Relevant to these NAAG peptidase
inhibition data, the periaquaductal grey contains a rela-
tively high concentration of both NAAG and NAAG pepti-
dase activity [29]. Further, group II mGluR agonist
activation of presynaptic receptors on GABAergic neurons
in the periaquaductal grey reduces GABA release [37]. We
previously reported that NAAG inhibits GABA release
from cortical neurons via a presynaptic mechanism [5]. A
similar action of presynaptic opiate receptors on GABAer-
gic neurons in the periaquaductal grey disinhibits a
descending pathway that suppresses nociceptive transmis-
sion in the dorsal horn of the spinal cord [36,39]. While
these data are consistent with speculation that intracere-
broventricular administration of NAAG peptidase inhibi-
tors might achieve analgesia via a mechanism that
parallels that of the opiates in the PAG, a dose response
study directly in the PAG is required to demonstrate this
site of action. More importantly, these data together with
our previous studies suggest that this peptide transmitter
functions both spinally and centrally along pathways that
mediate and modulate perception of inflammatory pain
in a manner that is analogous to opiate peptides.
Given the wide distribution of group II mGluR receptors
in the brain, it is surprising that direct infusion of NAAG
did not result in a broad range of behavioral effects out-
side of the pain modulatory pathway and that its effects
on the pain responses were not at least as profound as
those of the peptidase inhibitors. This result is most likely
due to the equally widespread distribution of extracellular
NAAG peptidase activity in the brain. In the absence of
peptidase inhibition, NAAG delivered by ICV is likely to
be hydrolyzed rapidly as it diffuses through the extracellu-
lar space. Equally relevant to the development of new
analgesic drugs, the systemic administration of the pep-
tide would have the same drawbacks as synthetic group II
agonists. That is, agonists activate receptors without a rela-
tionship to the normal level of information movement
within circuits. In contrast, strategies that enhance the
actions of endogenously released transmitters, such as
NAAG peptidase inhibition, enhance the effects of the
normal action of the circuit. This is, for example, the basis
of the therapeutic efficacy of benzodiazepines, barbitu-
rates and serotonin selective reuptake inhibitors.
ZJ43 is tricarboxylic acid with a urea core. Its hydrophilic
structure contributes to its relatively low penetration
across the CACO-2 cell culture model of tight junctions as
found in the blood-brain barrier (Neale, et al., unpub-
lished data). As a result, it is not surprising that despite its
low nanomolar IC50 for NAAG peptidases, relatively high
(50–100 mg/kg) systemic doses of ZJ43 are required to
obtain significant analgesia in inflammatory and neuro-
pathic pain models [21]. This finding that some of the
analgesic effects of ZJ43 are obtained by acting at pain cir-
cuits that are accessible via the lateral ventricle militates in
favor of developing similarly potent NAAG peptidase
inhibitors that cross the blood brain barrier more effec-
tively. Toward this objective, we have synthesized a series
of prodrug esters of ZJ43 that are themselves not NAAG
peptidase inhibitors but that may enter the central nerv-
ous system more effectively due to their improved ClogP
values. In preliminary studies, some of these prodrugs are
more active in an inflammatory pain model than is ZJ43
(Yamamoto, unpublished). These results suggest that
some esters of ZJ43 penetrate the blood-brain barrier
effectively and are hydrolyzed efficiently by central nerv-
ous system esterases rather than by serum esterases. If
NAAG peptidase inhibition continues to show promise as
an analgesic pharmacotherapy, this prodrug development
strategy is likely to be important in reducing the amount
of drug required to achieve analgesia, thus reducing the
probability of secondary effects and toxicity in other tis-
sues.
Conclusion
NAAG and its receptors are present in circuits within the
brain and brainstem that process pain perception. This
study provides the first direct demonstration that NAAG
peptidase inhibitors reduce inflammatory pain percep-
tion by acting on pain communication pathways within
the brain. Currently, clinical therapy for pain is limited to
opioids and non-steroidal analgesics. This discovery of
the analgesic effects of NAAG and NAAG peptidase inhib-
itors in the brain represents an important step in under-
standing the cellular mechanism underlying this
promising new approach to analgesia.
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